Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Clinical trial NCT04116437 · COMPLETED

Trial details

NCT number: NCT04116437
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom Macroglobulinemia

Start date: 2019-10-15
Primary completion: 2026-01-09
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.